Indoco Remedies arm begins commercial production of Pharmaceutical Intermediates

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-03-26 10:00 GMT   |   Update On 2024-03-26 10:00 GMT

Mumbai: Warren Remedies Private Limited, a Wholly Owned Subsidiary of Indoco Remedies Limited has commenced its commercial production from its Greenfield manufacturing facility located at Aurangabad, Maharashtra to manufacture Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs). Commenting on this occasion, Aditi Panandikar, Managing Director-Indoco Remedies...

Login or Register to read the full article

Mumbai: Warren Remedies Private Limited, a Wholly Owned Subsidiary of Indoco Remedies Limited has commenced its commercial production from its Greenfield manufacturing facility located at Aurangabad, Maharashtra to manufacture Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs).

Commenting on this occasion, Aditi Panandikar, Managing Director-Indoco Remedies Ltd. said, “It gives us immense pleasure to announce that Warren Remedies Private Limited, Wholly Owned Subsidiary of Indoco Remedies has commenced its commercial production of Pharmaceutical Intermediates to cater to the needs of its customers. The said manufacturing facility will provide us requisite capabilities and edge in meeting demand of APIs.”

Medical Dialogues team had earlier reported that Warren Remedies had commenced its commercial production on March 1, 2024, from its Greenfield manufacturing facility located at Aurangabad, Maharashtra, to manufacture Oral Care Products.

Read also: Indoco Remedies arm commences commercial production of oral care products

Indoco is a fully integrated, research-oriented pharmaceutical company with pa resence in 55 countries. The Company’s turnover is US$ 200 million with a human capital of 6000 employees, including over 300 skilled scientists and Field Staff.

The Company has nine manufacturing facilities, 6 for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by most of the Regulatory Authorities including the USFDA and UK-MHRA.

Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 109 million prescriptions annually from over 3,00,000 doctors belonging to various specialties.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Gastro-intestinal, Respiratory, Anti-Infective, Stomatologicals, Ophthalmic, Nutritionals, Cardiovascular, Anti-Diabetics, Pain Management, Gyneacology etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Sensoform, Sensodent-KF, Cloben-G, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Homide, Cal-Aid, etc. On the international front, Indoco has tie-ups with large generic companies across the globe.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News